Brief: Oramed Reaches 50% Enrollment In Its Second Phase 3 Oral Insulin Trial
26/07/2022 12:56
July 26 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O :
* ORAMED REACHES 50% ENROLLMENT IN ITS SECOND PHASE 3 ORAL
INSULIN
TRIAL
* ORAMED PHARMACEUTICALS INC - ORA-D-013-1, LARGER OF TWO
TRIALS,
COMPLETED ENROLLMENT WITH TOP LINE DATA EXPECTED JANUARY 2023
Source text for Eikon: ID:nPnX2xGja
Further company coverage: ORMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results